Bradycardia associated with ALK inhibitors in the treatment of non-small cell lung cancers: a systematic review and meta-analysis

被引：0
|
作者：
Zhou, S. [1 ]
Cirne, F. [1 ]
Kappel, C. [1 ]
El-Kadi, A. [1 ]
Ellis, P. [1 ]
Leong, D. P. [2 ]
机构：
[1] McMaster Univ, Hamilton, ON, Canada
[2] Populat Hlth Res Inst, Hamilton, ON, Canada
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2848 / 2848
页数：1
相关论文
共 50 条
  • [1] ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
    Elliott, Jesse
    Bai, Zemin
    Hsieh, Shu-Ching
    Kelly, Shannon E.
    Chen, Li
    Skidmore, Becky
    Yousef, Said
    Zheng, Carine
    Stewart, David J.
    Wells, George A.
    PLOS ONE, 2020, 15 (02):
  • [2] Effect of ALK-inhibitors in the treatment of non-small cell lung cancer: a systematic review and meta-analysis
    Li, G.
    Dai, W. -R.
    Shao, F. -C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (15) : 3496 - 3503
  • [3] Efficacy and Safety of ALK Inhibitors in ALK-Rearranged Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Breadner, D.
    Shanmuganatjan, S.
    Boldt, G.
    Blanchette, P.
    Raphael, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1034 - S1034
  • [4] Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
    Breadner, Daniel
    Blanchette, Phillip
    Shanmuganathan, Sumugan
    Boldt, Ronald Gabriel
    Raphael, Jacques
    LUNG CANCER, 2020, 144 : 57 - 63
  • [5] ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis
    Jiang, Jun
    Zhao, Cong
    Zhang, Fang
    Liu, Zhenhua
    Zhou, Kaiyuan
    Ren, Xinling
    Wan, Yi
    BMJ OPEN, 2022, 12 (09):
  • [6] ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis
    Pyo, Jung-Soo
    Kang, Guhyun
    Sohn, Jin Hee
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2016, 31 (04): : E413 - E421
  • [7] The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis
    Fan, Junsheng
    Fong, Tszhei
    Xia, Zengfei
    Zhang, Jian
    Luo, Peng
    CANCER MEDICINE, 2018, 7 (10): : 4993 - 5005
  • [8] Efficacy of ALK Inhibitors in the Treatment of ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases: A Meta-analysis
    Luo, P.
    Fan, J.
    Zou, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2373 - S2373
  • [9] Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: A systematic review and meta-analysis
    Xing, Puyuan
    Hao, Xuezhi
    Zhang, Xin
    Li, Junling
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Zeng, Qinghua
    Zhang, Xiquan
    He, Shan
    Zhou, Zhiyong
    Xia, Luping
    Zhang, Wenxiong
    Zeng, Lin
    CHEMOTHERAPY, 2022, 67 (02) : 67 - 80
12345